Abstract
Breast cancer is the most commonly diagnosed malignancy for women living in the United States and more than 26,000 newly diagnosed patients per year are under the age of 45.1 Given that most chemotherapeutic agents and hormonal therapies used for adjuvant treatment of breast cancer are gonadotoxic and/or teratogenic, fertility preservation is critical prior to initiating treatment. Increased awareness of the need to preserve fertility, timely referral to infertility specialists, and development of ovarian stimulation protocols that are safe in breast cancer patients have increased rates of fertility consultation and treatment among women diagnosed with breast cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
